Pharmaceutical Technology

MAY 19, 2023

Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase I/II trials for T cell lymphoma. The financing will help to fast-track the development of other in vivo programming candidates into clinical trials.

In-Vivo 246

In-Vivo Gene Therapy Gene RNA 246

pharmaphorum

SEPTEMBER 28, 2021

The 4th RNA-Targeted Drug Discovery Summit is returning once again this December, to reunite the largest community of thought leaders and experts in biology, chemistry and RNA therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity, selectivity and drug-like properties.

RNA 52

RNA Drugs Clinical Development Development 52

BioSpace

AUGUST 24, 2021

Funds will be used to advance the clinical development of Cardior’s lead program, CDR132L, an oligonucleotide-based ncRNA inhibitor targeting micro-RNA-132.

RNA 75

RNA Clinical Development Development 75

BioTech 365

OCTOBER 14, 2020

DUBLIN–(BUSINESS WIRE)–The “RNA Therapies in Oncology: Analytical Tool” report has been added to ResearchAndMarkets.com’s offering.

RNA 40

RNA Business Development Clinical Development Development 40

Outsourcing Pharma

JANUARY 17, 2023

SanegeneBio has formed a service agreement with Orbit Discovery to support tissue-specific delivery of a wide range of RNA therapeutics.

RNA 52

RNA Clinical Development Development 52

pharmaphorum

SEPTEMBER 23, 2020

Programmable Oligonucleotide Delivery System (PODS), developed by Sixfold Bioscience, is a versatile system which delivers short interfering RNA (siRNA) gene silencing cargo to specific cancer cells.

Drug Delivery Systems 141

Drug Delivery Systems Gene Silencing Drug Delivery Medicine 141

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 105

RNA Genetics Dermatology Antibody 105

BioTech 365

AUGUST 25, 2021

Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease Oversubscribed round enables late-stage clinical development of lead … Continue reading →

RNA 40

RNA Clinical Development Development 40

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccine Vaccination Development 40

BioTech 365

SEPTEMBER 10, 2020

Funding, led by aMoon, will advance the clinical development of MiNA’s new class of RNA therapeutics for cancer treatment, and further expand its R&D pipeline in additional disease areas LONDON–(BUSINESS WIRE)–MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today … Continue reading →

RNA 40

RNA Clinical Development Development 40

pharmaphorum

APRIL 19, 2022

The funding will be used to continue the clinical development of lead oligonucleotide PGN-EDO51 for DMD, as well as two other oligo drugs PGN-EDODM1 for myotonic dystrophy type 1 (DM1) and PGN-EDO53, another DMD candidate. Once there, they disrupt the expression of RNA coding for disease-associated proteins.

Protein 105

Protein RNA Clinical Development Production 105

Pharmaceutical Technology

DECEMBER 14, 2022

The discovery alliance, with a preliminary research period of four years, will aid GSK in progressing up to eight programmes and Wave to develop up to three programmes. An RNA editing therapy, WVE-006, could act on AATD’s liver and lung manifestations. According to the deal, GSK will make an upfront payment of $170m to Wave.

Life Science 162

Life Science Development Gene Therapy Genetics 162

The Pharma Data

OCTOBER 21, 2020

and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme.

Clinical Development 52

Clinical Development Development Medicine Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 22, 2023

CMN-005 is under clinical development by CoImmune and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). CoImmune is headquartered in Durham, North Carolina, the US. For a complete picture of CMN-005’s drug-specific PTSR and LoA scores, buy the report here.

RNA 100

RNA Development Drugs Clinical Trials 100

BioTech 365

NOVEMBER 18, 2021

Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program Discontinuing Clinical Development of EDP-721, an Oral HBV RNA Destabilizer Continuing to Focus on Development of EDP-514 in … Continue reading →

RNA 40

RNA Clinical Development Development 40

pharmaphorum

NOVEMBER 17, 2020

There are 11 potential COVID vaccines in late-stage clinical development and since Pfizer’s announcement two more groups from Russia’s Gamaleya Research Institute and US biotech Moderna have published favourable efficacy results. Pfizer and BioNTech have a $1.95

Vaccine 77

Vaccine Vaccination RNA Clinical Trials 77

pharmaphorum

DECEMBER 7, 2020

China’s Sinovac has raised $515 million to increase its distribution and production capacity as clinical development of its potential coronavirus vaccine nears conclusion. Sinovac has a coronavirus vaccine in late-stage development, which is undergoing large-scale trials in Brazil, Pakistan, Indonesia and Chile.

Vaccine 59

Vaccine Vaccination Production Clinical Development 59

Delveinsight

SEPTEMBER 14, 2021

ADARx bags USD 75 Million to advance its RNA tech pipeline. ADARx Pharmaceuticals, a biotechnology company developing RNA targeting therapeutics , announced the completion of a USD 75 million Series B financing to progress its drug development pipeline. SR One Capital Management and OrbiMed Advisors co-led Series B.

RNA 67

RNA Clinical Trials Clinical Trials Drugs 67

pharmaphorum

FEBRUARY 19, 2021

CEPI has provided early support to Novavax’s effort to develop a COVID vaccine, including the commitment of around $400 million to early clinical development and manufacturing scale-up in several facilities around the globe. The post Novavax provides 1.1 billion COVID shots to global vaccine drive appeared first on.

Vaccine 80

Vaccine Vaccination Manufacturing RNA 80

pharmaphorum

OCTOBER 6, 2020

The vaccine is based on different technology from AZ’s rival: while AZ’s uses a weakened and genetically modified cold virus to prime the immune system, BNT162b2 is based on a string of RNA. According to latest figures from the World Health Organization, there are 42 potential COVID-19 vaccines in clinical development.

Vaccine 59

Vaccine Vaccination RNA Immune Response 59

pharmaphorum

NOVEMBER 18, 2021

The two companies have been working together since 2019 to develop multiple RNA interference (RNAi) candidates for disorders such as non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases. billion in cash. If approved, it could become a $500 million-a-year product, according to the company.

Gene Silencing 52

Gene Silencing RNA Protein Gene 52

Worldwide Clinical Trials

JUNE 15, 2022

Further, some patients are still hesitant to go into the clinic, and the prevalence of misinformation from the pandemic has led to greater concerns about therapies like gene therapies and the impact they fear it will have on their RNA/DNA. The cell and gene therapy pipeline is booming.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

XTalks

JUNE 14, 2023

More Drugs for Dry Eye Disease Are on the Way Several other drugs have recently gained FDA approval or are currently in advanced stages of clinical development for the treatment of dry eye disease. One such approved medication is Miebo , an ophthalmic solution developed by Bausch + Lomb and Novaliq.

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

The Pharma Data

AUGUST 12, 2020

Moderna continues to rise to meet the demands of the pandemic, signing a new deal with the US Government to supply 100 million doses of its messenger RNA (mRNA) vaccine candidate for the prevention of COVID-19.

Vaccine 52

Vaccine Vaccination Manufacturing RNA 52

pharmaphorum

JANUARY 7, 2021

At last count, there are more than 60 coronavirus vaccines at in clinical development around the world, with another 170 in preclinical testing, according to the World Health Organization (WHO). The post Bayer joins the COVID-19 vaccine push, backing CureVac shot appeared first on.

Vaccine 105

Vaccine Vaccination Contract Manufacturing Development 105

The Pharma Data

OCTOBER 25, 2020

We are advancing the clinical development of mRNA-1273 with our Phase 3 COVE study, which is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Vaccine 52

Vaccine Vaccination Manufacturing Clinical Development 52

XTalks

JANUARY 3, 2024

The collaboration builds upon the companies’ prior work together since March 2022, with Novartis further investing in the research and development of treatments for the neurological disorders​​. Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACER capsids and other intellectual property.

Gene Therapy 52

Gene Therapy Gene Licensing Licensing 52

The Pharma Data

MARCH 8, 2021

Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Molnupiravir.

Trials 69

Trials In-Vivo Genotoxicity RNA 69

pharmaphorum

MARCH 29, 2022

We designed BIIB078 to test the prevailing hypothesis that the mechanisms of disease for C9orf72-associated ALS were caused by toxicity associated with the repeat containing RNA and corresponding dipeptides,” said C. Frank Bennett, executive vice president, chief scientific officer and franchise leader for neurological programs at Ionis.

Trials 49

Trials RNA Containment Genetics 49

The Pharma Data

DECEMBER 8, 2020

Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. Laying down a new track for RNA processing, Remix launched with $81 million in financing. Sigilon Therapeutics .

RNA 52

RNA Antibody Life Science Protein 52

The Pharma Data

DECEMBER 3, 2020

Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines. The Phase 1 clinical trial was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).

Vaccine 52

Vaccine Vaccination Immune Response Protein 52

The Pharma Data

OCTOBER 14, 2020

is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.

Protein 52

Protein RNA Production Genetics 52

The Pharma Data

JANUARY 31, 2021

These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.” Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccine Vaccination 52

The Pharma Data

JULY 12, 2021

“It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If About Molnupiravir.

Clinical Trials 52

Clinical Trials Clinical Trials Bioavailability Trials 52

The Pharma Data

DECEMBER 13, 2020

Dr. Kehua Fan has over 15 years of Business Development, Clinical Development of innovative drugs and other healthcare industry experience with MNCs and biotech companies. He received his B.S. degree from Henan Normal University, M.S. degree from Chinese Academy of Sciences and Ph.D. from University of New Hampshire.

Business Development 40

Business Development Development Gene Editing In-Vivo 40

The Pharma Data

OCTOBER 28, 2020

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co., 29, 2020 06:00 UTC. CAMBRIDGE, Mass.–(

Vaccine 40

Vaccine Vaccination Manufacturing Clinical Trials 40

Pharma Marketing Network

DECEMBER 21, 2020

those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. For example, “gene silencing” is a less-than-ideal description for the mechanism of RNA interference (RNAi) therapeutics.

Genetics 52

Genetics Medicine Gene Therapy Marketing 52